Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First in Human Study of TOS-358 in Adults with Solid Tumors
2023-505346-26-01Phase 2Authorised
- Sponsor
- Totus Medicines
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, single-arm trial of TOS-358 in colorectal cancer (CRC), Cervical Cancer (CC), endometrial cancer (EC) and 6 more, sponsored by Totus Medicines. Planned start Jan 2024; status: authorised.
02
Drugs
TOS-358
03
Conditions
colorectal cancer (CRC)Cervical Cancer (CC)endometrial cancer (EC)gastric cancer (GC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2023-505346-26-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505346-26-01.